Charles Slacik will join Beckman Coulter as senior vice president and CFO, effective Oct. 23. He joins the firm from Watson Pharmaceuticals, where he currently serves as executive vice president and CFO. Previous to working at Watson, Slacik was senior vice president and CFO of medical device manufacturer CR Bard.
 

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.